Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy

Blood

Volumn 124, Issue 23, 2014, Pages 3490-3500

  Van Der Waart, Anniek B ^a   Van De Weem, Noortje M P ^a   Maas, Frans ^a   Kramer, Cynthia S M ^a   Kester, Michel G D ^b   Falkenburg, J H Frederik ^b   Schaap, Nicolaas ^a   Jansen, Joop H ^a   Van Der Voort, Robbert ^a   Gattinoni, Luca ^c   Hobo, Willemijn ^a   Dolstra, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3-DIHYDRO-1-(1-((4-(6-PHENYL-1H-IMIDAZO(4,5-G)QUINOXALIN-7-YL)PHENYL)METHYL)-4-PIPERIDINYL)-2H-BENZIMIDAZOL-2-ONE; BENZIMIDAZOLE DERIVATIVE; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUINOXALINE DERIVATIVE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; MULTIMODALITY CANCER THERAPY; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; BENZIMIDAZOLES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; SIGNAL TRANSDUCTION; TRANSPLANTATION CONDITIONING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914159677     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578583     Document Type: Article

References (44)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001; 411(6835):385-389
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-221
3. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-4383
4. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31(9):743-751
5. Klebanoff CA, Gattinoni L, Restifo NP. CD81 T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211: 214-224
6. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27(1):55-62
7. Kennedy-Nasser AA, Bollard CM. T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI? Bone Marrow Transplant. 2007;40(2):93-104
8. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352
9. Stemberger C, Dreher S, Tschulik C, et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS ONE. 2012;7(4):e35798
10. Butler MO, Lee JS, Ans̈en S, et al. Long-lived antitumor CD81 lymphocytes for adoptive therapy generated using an artificial antigenpresenting cell. Clin Cancer Res. 2007;13(6): 1857-1867
11. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671-684
12. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD81 memory stem cells. Nat Med. 2009;15(7):808-813
13. Hinrichs CS, Borman ZA, Gattinoni L, et al. Human effector CD81 T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 2011; 117(3):808-814
14. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297
15. Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(1) central memory T cells. Immunity. 2014;41(1): 116-126
16. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. 2013;4:20
17. Yoo JK, Cho JH, Lee SW, Sung YC. IL-12 provides proliferation and survival signals to murine CD41 T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol. 2002; 169(7):3637-3643
18. Kim EH, Sullivan JA, Plisch EH, et al. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol. 2012; 188(9):4305-4314
19. Rao RR, Li Q, Gubbels Bupp MR, Shrikant PA. Transcription factor Foxo1 represses T-betmediated effector functions and promotes memory CD8(1) T cell differentiation. Immunity. 2012;36(3):374-387
20. Hobo W, Broen K, van der Velden WJ, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(2): 274-282
21. Hobo W, Novobrantseva TI, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. 2013;62(2):285-297
22. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 2008;105(33):11915-11920
23. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279(5353):1054-1057
24. Van Bergen CA, Rutten CE, Van Der Meijden ED, et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res. 2010; 70(22):9073-9083
25. Nijman HW, Houbiers JG, Vierboom MP, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993;23(6): 1215-1219
26. Cany J, van der Waart AB, Tordoir M, et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PLoS ONE. 2013;8(6):e64384
27. Hobo W, Norde WJ, Schaap N, et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD81 T cells in patients after allogeneic stem cell transplantation. J Immunol. 2012;189(1):39-49
28. van der Waart AB, van der Velden WJ, van Halteren AG, et al. Decreased levels of circulating IL17-producing CD1611CCR61 T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation. PLoS ONE. 2012;7(12): e50896
29. Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013; 121(4):573-584
30. Lugli E, Gattinoni L, Roberto A, et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc. 2013;8(1):33-42
31. Yang S, Ji Y, Gattinoni L, et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 2013;62(4):727-736
32. Bondanza A, Hambach L, Aghai Z, et al. IL-7 receptor expression identifies suicide genemodified allospecific CD81 T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 2011;117(24): 6469-6478
33. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide genemodified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009; 113(5):1006-1015
34. + T-cell development. Nat Commun. 2013;4: 2830
35. Joshi NS, Cui W, Chandele A, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007; 27(2):281-295
36. Kim HT, Armand P. Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom. Biol Blood Marrow Transplant. 2013;19(6): 860-866
37. Rezvani AR, Storb RF. Separation of graft-vs.- tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008;30(3):172-179
38. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81(3):445-454
39. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD271 subset of human CD41CD251 regulatory T cells. Blood. 2006;107(3):1018-1023
40. Wang Y, Godec J, Ben-Aissa K, et al. The transcription factors T-bet and Runx are required for the ontogeny of pathogenic interferong- producing T helper 17 cells. Immunity. 2014; 40(3):355-366
41. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4(12): 1191-1198
42. Kim HR, Hong MS, Dan JM, Kang I. Altered IL-7Ralpha expression with aging and the potential implications of IL-7 therapy on CD81 T-cell immune responses. Blood. 2006;107(7): 2855-2862
43. Beider K, Nagler A, Wald O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood. 2003;102(6): 1951-1958
44. Dunussi-Joannopoulos K, Zuberek K, Runyon K, et al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-celldependent antitumor responses. Blood. 2002; 100(5):1551-1558.